Vanguard Group Inc Inhibrx, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Inhibrx, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,861,469 shares of INBX stock, worth $28.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,861,469

Previous 1,874,323 0.69%

Holding current value

$28.1 Million

Previous $71.2 Million 8.63%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$32.76 - $39.56 $421,097 - $508,504	-12,854 Reduced 0.69%	1,861,469 $65.1 Million
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $1.23 Million - $3.21 Million	84,512 Added 4.72%	1,874,323 $71.2 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $287,768 - $480,710	18,271 Added 1.03%	1,789,811 $32.8 Million
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $63,447 - $104,074	-3,741 Reduced 0.21%	1,771,540 $46 Million
Q1 2023 May 15, 2023	BUY	$18.45 - $27.14 $275,052 - $404,603	14,908 Added 0.85%	1,775,281 $33.5 Million

Q4 2022 Feb 10, 2023	BUY	$20.18 - $33.33 $5.9 Million - $9.75 Million	292,455 Added 19.92%	1,760,373 $43.4 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $1.29 Million - $2.76 Million	111,802 Added 8.24%	1,467,918 $26.3 Million
Q2 2022 Aug 12, 2022	BUY	$8.52 - $25.26 $1.18 Million - $3.49 Million	138,003 Added 11.33%	1,356,116 $15.4 Million
Q1 2022 May 13, 2022	BUY	$19.89 - $43.18 $226,049 - $490,740	11,365 Added 0.94%	1,218,113 $27.1 Million
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $14.1 Million - $24.3 Million	527,223 Added 77.59%	1,206,748 $52.7 Million
Q3 2021 Nov 12, 2021	BUY	$25.18 - $37.81 $4.65 Million - $6.98 Million	184,676 Added 37.32%	679,525 $22.6 Million
Q2 2021 Aug 13, 2021	BUY	$14.69 - $27.52 $7.27 Million - $13.6 Million	494,849 New	494,849 $13.6 Million

Others Institutions Holding INBX

# of Institutions

132

Shares Held

35.5M

Call Options Held

64.8K

Put Options Held

91.3K

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $589M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Inhibrx, Inc. Transaction History